Plasma
New EU’s pharma rules: a game-changer for strategic autonomy on plasma?
Ensuring sufficient plasma collection in Europe remains a thorny issue but the forthcoming revision of the EU framework for pharmaceuticals offers the potential to turn the tide.
MEP: Clear EU definition of plasma would pave way for better awareness
Communication about the importance of plasma donations can be improved by focusing on a clear definition in the EU legislation, ensuring that more awareness is raised about the role it plays in producing life-saving medical products, a centre-right EU lawmaker told EURACTIV.
Commission: EU’s new blood directive to address dependency on US plasma
The ongoing revision of the European legislation on blood, tissues, and cells offers an opportunity to tackle the highly problematic dependency on plasma collected in the US for manufacturing plasma-derived medicinal products (PDMPs), according to an EU health official.
COVID-19 plasma therapy comes handy either way, EU Commission says
Even though the efficiency of plasma therapies against COVID-19 are not yet demonstrated, increasing Europe's blood collection capacity will contribute to address chronic shortages, the European Commission has said.
COVID-19 pandemic casts new light on plasma therapies
The use of COVID-19 convalescent plasma (CCP) as a therapeutic option, despite its ups and downs, has shown the European Union's renewed interest in plasma-derived medicinal products (PDMPs).Supporter
This stakeholder supports EURACTIV's coverage of Plasma. This support enables EURACTIV to devote additional editorial resources to cover the topic more widely and deeply. EURACTIV's editorial content is independent from the views of its supporters.
The Plasma Protein Therapeutics Association (PPTA) is the global industry trade association with a strong European presence representing the private sector manufacturers of plasma-derived medicinal products (PDMPs), and privately-owned plasma donation centres, which includes more than 150 centres in Europe. PPTA is steadfast in its mission to promote the availability of, and access to, safe and effective plasma protein therapies for patients around the world.
